Skip to main content
. Author manuscript; available in PMC: 2014 May 20.
Published in final edited form as: Clin Cancer Res. 2011 Jul 7;17(16):5367–5378. doi: 10.1158/1078-0432.CCR-10-3176

Figure 5. In vivo anti-tumor effects of combination therapy with oxaliplatin and dasatinib in mucinous ovarian carcinoma.

Figure 5

(A) Tumor weight (upper figures) and number of nodules (lower figures) are shown for 4 groups. Treatment was started 4 weeks from RMUG-S-ip2 injection and continued for 8 weeks. Bar represents mean with SE. (B) Immunohistochemistry staining for phospho-src (p-src), src kinase, Ki67, CD31 is shown in 4 groups. Negative control: no primary antibody used, and human IgG Ab: human IgG antibody was used as primary antibody. Arrow head: focal increased expression of phospho-src in tumors treated with oxaliplatin. For Ki67 staining, * p<0.01, § p<0.0001, compared to control (number of positive Ki67 cells per ×100 field). For CD31 staining, ¶ p<0.05, † p<0.01, compared to control. MVD, microvessel density (number of microvessel per ×200 field).